Planned Solutions Inc. Buys New Holdings in Novo Nordisk A/S (NYSE:NVO)

Planned Solutions Inc. acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,878 shares of the company’s stock, valued at approximately $194,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Roundview Capital LLC grew its position in shares of Novo Nordisk A/S by 0.6% during the first quarter. Roundview Capital LLC now owns 18,803 shares of the company’s stock worth $2,088,000 after acquiring an additional 106 shares during the last quarter. BlackRock Inc. grew its position in Novo Nordisk A/S by 45.4% in the 1st quarter. BlackRock Inc. now owns 5,035,879 shares of the company’s stock valued at $559,235,000 after buying an additional 1,571,747 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Novo Nordisk A/S by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 739,585 shares of the company’s stock valued at $82,131,000 after buying an additional 6,903 shares during the last quarter. Blair William & Co. IL grew its position in Novo Nordisk A/S by 12.7% in the 1st quarter. Blair William & Co. IL now owns 19,466 shares of the company’s stock valued at $2,136,000 after buying an additional 2,194 shares during the last quarter. Finally, Sei Investments Co. grew its position in Novo Nordisk A/S by 17.5% in the 1st quarter. Sei Investments Co. now owns 107,175 shares of the company’s stock valued at $11,913,000 after buying an additional 15,996 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. TD Cowen lifted their price objective on shares of Novo Nordisk A/S from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Monday, December 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, March 20th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price for the company. Finally, UBS Group assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $126.25.

Novo Nordisk A/S Stock Down 1.1 %

NYSE NVO opened at $128.05 on Thursday. The stock has a market cap of $574.63 billion, a PE ratio of 47.34, a P/E/G ratio of 2.13 and a beta of 0.41. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The business has a 50 day moving average price of $121.34 and a two-hundred day moving average price of $104.22. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.35 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a Semi-Annual dividend, which will be paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th will be given a $0.664 dividend. This represents a dividend yield of 0.9%. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date is Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio is presently 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.